Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 at Citizens Jmp

Protagonist Therapeutics (NASDAQ:PTGX) had its price objective increased by Citizens Jmp from $102.00 to $112.00 in a report released on Thursday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other equities analysts also recently weighed in on the company. Citigroup boosted their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Barclays boosted their price objective on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Jefferies Financial Group raised their target price on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Truist Financial upped their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, HC Wainwright increased their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.31.

Protagonist Therapeutics Trading Up 1.5%

Shares of NASDAQ PTGX opened at $88.39 on Thursday. Protagonist Therapeutics has a 12-month low of $35.95 and a 12-month high of $96.54. The firm’s 50-day moving average price is $84.12 and its 200-day moving average price is $76.59. The stock has a market capitalization of $5.53 billion, a price-to-earnings ratio of -43.12 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.50% and a negative net margin of 282.83%.The company had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. On average, equities analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Protagonist Therapeutics news, CFO Asif Ali sold 46,203 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the sale, the chief financial officer directly owned 60,320 shares of the company’s stock, valued at $5,014,401.60. The trade was a 43.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the transaction, the director owned 7,825 shares in the company, valued at $654,796. This represents a 71.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,167 shares of company stock worth $16,889,199 over the last ninety days. 4.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in shares of Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after buying an additional 146 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in Protagonist Therapeutics by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock worth $1,170,000 after acquiring an additional 193 shares in the last quarter. Maryland State Retirement & Pension System increased its position in Protagonist Therapeutics by 2.3% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock valued at $751,000 after purchasing an additional 196 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Protagonist Therapeutics by 8.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after purchasing an additional 221 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics News Summary

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Several brokers raised ratings and price targets this morning, signaling renewed analyst conviction (higher targets increase upside perception). Barclays raised its target to $113 and kept an “overweight” rating. Barclays Raises PT to $113
• Positive Sentiment: Citizens JMP bumped its target to $112 and maintained a “market outperform” view, adding to the upward pressure on investor expectations. Citizens JMP Raises PT to $112
• Positive Sentiment: TD Cowen raised its target to $100 and reaffirmed a “buy” rating, giving additional dealer support for further gains. TD Cowen Raises PT to $100
• Positive Sentiment: Company corporate update: Protagonist submitted an NDA for rusfertide to the FDA (potential approval/launch this year), expects a U.S. regulatory decision for ICOTYDE (icotrokinra) in 2026 with potential launch, may opt out of a 50:50 profit/loss sharing deal with Takeda (90‑day window expected in Q2), expects PN‑881 Phase 1 completion by mid‑2026, and expanded its preclinical pipeline — all items that materially improve medium‑term commercial and revenue prospects. Corporate Update / Correction
• Neutral Sentiment: Press coverage and earnings snapshot pieces summarizing the quarter and corporate update provide broader market context but add no new facts beyond the company release. Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: reported EPS of ($0.69) vs. consensus ($0.53) and revenue $7.44M vs. $14.92M est. The revenue shortfall and EPS miss add short‑term execution risk and raise questions about near‑term cash flow. Q4 Results / Press Release
• Negative Sentiment: Hedge fund BVF disclosed a large Q4 exit, selling ~2.56M PTGX shares (≈$170M at quarter‑end), which could increase supply pressure if other holders follow. BVF Share Sale

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.